Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited has issued 750,960,477 ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The company has complied with relevant provisions of the Corporations Act and confirms there is no excluded information required to be disclosed, indicating a strategic move to strengthen its financial position and potentially expand its market presence.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the healthcare industry, focusing on the development and commercialization of radiopharmaceutical products. These products are primarily used for diagnostic and therapeutic purposes, positioning the company within the niche market of theranostics.
Average Trading Volume: 5,896,644
Technical Sentiment Signal: Sell
Current Market Cap: A$61.17M
See more data about RAD stock on TipRanks’ Stock Analysis page.